Plant-based food is slowly but surely bringing about a revolution in the food industry, and over the past few years, many new companies have sprung up that cater to different markets. One of the most exciting companies to have emerged in this sector in recent years is Else Nutrition Holdings.
As everyone knows, plenty of plant-based companies have been established in recent years, but there are only a handful of companies that are involved in manufacturing plant-based nutrition for babies. Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF) is involved in this niche space and has quickly become one of the names to keep in mind.
5 Major Points for Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF)
- Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF) has quickly moved to meet parents’ demand with a breakthrough, science-backed formula that is the first 100% plant based, non-dairy, and non-soy baby formula.
- On January 22nd, Else Nutrition received a formal notice of allowance from the U.S. Patent & Trademark Office for the extension of the Company’s existing patents to cover the market of adults suffering from malnutrition.
- Market ready, the advanced stage Else Baby Formula for Toddlers (ages 12 months to 36 months) is scheduled to launch in Q2 2020, in powder and liquid forms. On top of that, the company has many other products in development. Considering the strong products pipeline, Else Nutrition Holdings Inc. (TSX.V:BABY) might be in better position to outperform in the industry in 2020.
- Through the sale of its vegan baby snacks, bottles and accessories in Israel, the company is already generating revenue — US$0.90 Million in 2018.
- The Stock has been gaining consistent momentum and Else Nutrition’s stock closed at 4-month high.
Else Nutrition Holdings’ (TSX.V: BABY) (OTCQB: BABYF) stock closed at 4-month high at C$0.51.
The stock has gained about 60% in the past 6-Week as the momentum was strong throughout this period.
On December 19th, the stock had witnessed its highest one-day volume of 655.79K since early September – over 5X its 3-month average volume.
BABY’s stock is trading well above all the major key Moving Averages, and 20-Day MA is trading above the 50-Day MA, meaning short-term uptrend is likely to intact.
Moreover, the stock has formed higher lows and higher highs on the daily price trend line – signaling the stock has witnessed buying activities on every small dip.
The stock has strong support at $0.44 and may not face major hurdles before $0.62-0.65.
Else Nutrition Holdings Has Several Upcoming Catalysts in 2020
Else Nutrition Holdings Inc. (TSX.V:BABY) (OTCQB:BABYF) has created its very own baby food formula that could disrupt the massive industry considerably. The company’s baby food formula is completely plant-based, and there are other factors that make it unique. It has no elements of GMO, soy, or dairy whatsoever, and due to the rising demand for products of that nature, Else could well have a significant market to cater to in the years to come.
On the other hand, market research firms have also revealed that this is an industry that could grow into a mammoth money-spinner. As per Hexa Research, the industry could be worth as much as US$90.48 billion, and hence, it is quite clear that Else presents an interesting opportunity for investors.
The big advantage enjoyed by Else lies in the fact that the competing plant-based milk product all contain soy, and research has revealed that babies who might be allergic to cow’s milk are almost always allergic to soy as well. Hence, its unique formula opens up another major competitive advantage for Else.
However, there is another factor that could work to Else’s advantage in a big way. According to surveys, it has been revealed that out of every 12 families in the United States, one family is determined to raise their children as vegans. Hence, those families are going to feed their babies plant-based milk, and the formula created by Else seems like the perfect one. There is a genuine gap in the market when it comes to plant-based, non-soy, non-GMO, and non-dairy baby formula food.
Else Nutrition has the potential to fill up this gap, and hence, it is not a surprise that many market watchers are quietly excited about this company’s prospects.
One of the reasons why it is being said that the infant baby formula is ripe for disruption is that it is an industry that has not seen much innovation for more than a century. Different variants of the same cow milk products have been sold to parents over the decades. However, the whole industry is now on the verge of a revolution, owing to the demand for plant-based options, and Else Nutrition Holdings stands in the perfect position to take advantage of the situation.
Big Boost – Extension of the Company’s existing patents
However, all that can happen when the company’s products get the necessary proprietary protections that are vital for a unique product. In that regard, Else Nutrition got a massive boost from the United States Patent and Trademark Office on Wednesday. It should be noted that in addition to baby nutrition, the company is also involved in making products meant for the adult market.
The federal agency extended Else Nutrition’s existing patents that pertain to products that relate to the adult malnutrition market. The patent is a significant one for the company since Else now wants to use its proprietary formula to develop products for adults who might be suffering from malnutrition. The product that was patented offers adults with the necessary amino acids, proteins, and other nutrients that are generally available in one serving.
This is a massive boost for Else Nutrition since it further strengthens the company’s intellectual property portfolio in the United States.
Moreover, such a strong intellectual property portfolio is also going to work in the company’s favor as and when it launches its products in the United States. The Chief Executive Officer of Else, Hamutal Yitzhak stated that the company aims to launch its products in the United States later this year.
He went on to add, “Our 100% plant-based formulation has functional and meaningful applications to a wide range of potential consumer markets.” However, he was quick to add that Else is ‘laser-focused’ on the launch of the company’s baby food products later on this year in the United States.
That being said, the patent for the adult consumption product indicates that the company is also looking at ways in which it can address the booming plant-based food market in the United States.
At this point in time, the plant-based food market in the country is worth $5 billion, and it is only going to grow in the years to come. Hence, the extension of the patent is a major development for Else.
Important Notice & Disclaimer
*Never invest in a stock mentioned by Traders Insights unless you can afford to lose your entire investment.
Release of Liability: Through use of this website viewing or using you agree to hold Traders Insights, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Traders Insights’s employees do not own any shares of the mentioned company(s). Traders Insights will also disclose any compensation. Traders Insights has been compensated Seven Hundred dollars by Market Jar Media Inc for marketing efforts regarding BABYF.
Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. Traders Insights encourages readers and investors to supplement the information in this report with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Traders Insights makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Traders Insights, nor any of its affiliates are not registered investment advisors or a broker dealers.